Needless vaccination technology developed by the University of Queensland is due to be commercialised under funding by the Federal Government’s Innovation Investment Fund.

 

The Nanopatch technology will see less vaccine used than normal syringes, prevent needle-stick injuries and eliminate the need for vaccines to be refrigerated.

 

The product is being commercialised by Vaxxas Pty Ltd, a new company established with funding from the Innovation Investment Fund. The formation of Vaxxas will allow for clinical trials to be conducted within the next three years.

 

The research to develop Nanopatch has been eight years in the making and is led by Professor Mark Kendall at the Australian Institute for Bioengineering and Nanotechnology